Trametinib time to market

Trametinib was developed by GlaxoSmithKline (GSK). It was approved for marketing by the U.S. Food and Drug Administration (FDA) on May 29, 2013, and was approved for marketing by the China State Food and Drug Administration in March 2020.

Trametinib is indicated alone or in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in selected patients with BRAF V600E or V600K mutations, in combination with dabrafenib for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutations, and in combination with dabrafenib for the treatment of BRAF when no satisfactory locoregional treatment options are available Locally advanced or metastatic anaplastic thyroid cancer in patients with V600E mutations, in combination with dabrafenib, for the treatment of adult and pediatric patients ≥6 years of age with unresectable or metastatic solid tumors (excluding colorectal cancer) with BRAF V600E mutations that have progressed after prior therapy and for whom there are no satisfactory alternative treatments.

When used in combination with dabrafenib, perform dermatological evaluation every 2 months during treatment and continued for 6 months after discontinuation of combination therapy. Monitor for signs and symptoms of new noncutaneous malignancies. Assess LVEF by echocardiography or MUGA scan 1 month after the start of treatment and then every 2-3 months during treatment. During treatment, ophthalmological examinations were performed regularly based on clinical indications of visual impairment. Monitor closely for signs of colitis or gastrointestinal perforation. Monitor for symptoms of deep vein thrombosis or pulmonary embolism (e.g., shortness of breath, chest pain, swelling of arms or legs). Monitor for new or worsening serious skin reactions during treatment. Monitor blood glucose concentrations as clinically appropriate during combined therapy with trametinib and dabrafenib in patients with preexisting diabetes mellitus or hyperglycemia. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.